Insulet Corp. (PODD) Stock Price: $148.88+4.98 (+3.46%)
At close: Jun 24, 2026, 4:00 PM ET
The closing share price for Insulet Corp. (PODD) stock was $148.88 for Wednesday, June 24, 2026, up 3.46% on the day.
Longer view (total return, dividends reinvested): past 12 months -52.1% · 3-year avg -19.7%/yr · 5-year avg -11.7%/yr
PODD Price Chart
PODD is featured in
PODD Key Metrics
See All MetricsLAST CLOSE PRICE
$148.88
52-WEEK RANGE
$138.79 - $354.88
BETA
1.43
% FROM 52W HIGH
-58.05%
MARKET CAP
$10.31B
DIVIDEND YIELD
N/A
PE RATIO
trailing TTM
34.62
PE RATIO (FWD)
next-FY estimate
18.35
P/B RATIO
8.02
DEBT / EQUITY
0.69
REVENUE TTM
$2.90B
NET INCOME TTM
$302.80M
NET PROFIT MARGIN TTM
10.44%
TTM TOTAL RETURN
-52.14%
3Y TOTAL RETURN
-19.71%
5Y TOTAL RETURN
-11.68%
PODD Earnings Preview
Next Earnings Date
Aug 6, 2026
42 days away
EPS Estimate
1.45
Revenue Est.
$788.47M
Last Quarter Results
EPS
$1.42
vs Estimate
$1.19
Revenue
$761.70M
vs Estimate
$729.89M
PODD Analyst Ratings
Consensus Rating
Based on 23 analysts
Average Price Target
$242.43
+62.8% upside
Low
$165.00
Current
$148.88
High
$360.00
PODD Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2028 | $1.89 | $1.92 | $1.96 | 6 |
| Q2 2028 | $2.25 | $2.29 | $2.33 | 6 |
| Q3 2028 | $2.64 | $2.69 | $2.75 | 7 |
| Q4 2028 | $3.06 | $3.11 | $3.18 | 9 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $7.47 | $8.11 | $8.46 | 13 |
| FY 2028 | $9.61 | $10.21 | $10.55 | 7 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2028 | $1.03B | $1.04B | $1.06B | 6 |
| Q2 2028 | $1.09B | $1.11B | $1.13B | 6 |
| Q3 2028 | $1.18B | $1.20B | $1.21B | 11 |
| Q4 2028 | $1.29B | $1.31B | $1.33B | 6 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $3.78B | $3.95B | $4.03B | 18 |
| FY 2028 | $4.66B | $4.68B | $4.70B | 18 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
Related Stocks
HealthcarePODD Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PODD | $10.31B | $148.88 | +3.46% | -52.14% | -11.68% | +17.96% | — |
| 2WBA | $10.37B | $11.98 | +0.00% | +31.43% | -16.99% | -14.92% | vs PODD |
| 3BAX | $10.87B | $21.04 | +4.68% | -30.66% | -22.15% | -5.62% | vs PODD |
| 4CRL | $9.73B | $202.10 | +8.31% | +36.21% | -11.24% | +9.66% | vs PODD |
| 5HSIC | $9.38B | $80.10 | +1.82% | +13.36% | +1.86% | +2.09% | vs PODD |
| 6RVTY | $11.78B | $105.63 | +5.74% | +9.91% | -6.75% | +7.69% | vs PODD |
PODD Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy